New-onset diabetes mellitus: Predictive factors and impact on the outcome of patients undergoing liver transplantation

Current Diabetes Reviews

Volumn 9, Issue 1, 2013, Pages 78-85

  Sarno, Gerardo ^a,b   Mehta, Rucha J ^c   Guardado Mendoza, Rodolfo ^d   Jiménez Ceja, Lilia M ^d   De Rosa, Paride ^b   Muscogiuri, Giovanna ^a  

^a FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

^b UNIVERSITY HOSPITAL SAN GIOVANNI DI DIO E RUGGI D ARAGONA   (Italy)

^c WESTERN UNIVERSITY OF HEALTH SCIENCES   (United States)

^d UNIVERSITY OF GUANAJUATO   (Mexico)

Author keywords

HCV; Immunosuppressive therapy; Insulin resistance; Liver surgery; Liver transplantation; Metabolic syndrome; New onset diabetes mellitus; Nonalcoholic steatohepatitis

Indexed keywords

ACARBOSE; CALCINEURIN INHIBITOR; CORTICOSTEROID; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; INSULIN; MEGLITINIDE; METFORMIN; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; ROSIGLITAZONE; SULFONYLUREA; TACROLIMUS;

ALCOHOL LIVER CIRRHOSIS; ARTICLE; BODY MASS; CORTICOSTEROID THERAPY; DIABETES MELLITUS; ETHNICITY; GLYCEMIC CONTROL; GRAFT RECIPIENT; GROUPS BY AGE; HEPATITIS C; HUMAN; HYPERGLYCEMIA; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; INSULIN RELEASE; INSULIN TREATMENT; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; NEW ONSET DIABETES MELLITUS; NONHUMAN; OUTCOME ASSESSMENT; POSTOPERATIVE COMPLICATION; PREDICTIVE VALUE; PREOPERATIVE EVALUATION; PREVALENCE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SCREENING TEST; SURGICAL PATIENT;

EID: 84875956817     PISSN: 15733998     EISSN: 18756417     Source Type: Journal    
DOI: 10.2174/157339913804143234     Document Type: Article

References (80)

1. Cherqui D, Laurent A, Mocellin N, et al. Liver resection for transplantable hepatocellular carcinoma: long-term survival and role of secondary liver transplantation. Ann Surg 2009; 250(5): 738-746.
2. Caldwell SH, Crespo DM, Kang HS, Al-Osaimi AM. Obesity and hepatocellular carcinoma. Gastroenterology 2004; 127(5 Suppl 1): S97-103.
3. Anastacio LR, Ferreira LG, Ribeiro Hde S, et al. Metabolic syndrome after liver transplantation: prevalence and predictive factors. Nutrition 2011; 27(9): 931-937.
4. Cauble MS, Gilroy R, Sorrell MF, et al. Lipoatrophic diabetes and end-stage liver disease secondary to nonalcoholic steatohepatitis with recurrence after liver transplantation. Transplantation 2001; 71(7): 892-895.
5. Contos MJ, Cales W, Sterling RK, et al. Development of nonalcoholic fatty liver disease after orthotopic liver transplantation for cryptogenic cirrhosis. Liver Transpl 2001; 7(4): 363-373.
6. Roberts MS, Angus DC, Bryce CL, Valenta Z, Weissfeld L. Survival after liver transplantation in the United States: a diseasespecific analysis of the UNOS database. Liver Transpl 2004; 10(7): 886-897.
7. Malik S, Wong ND, Franklin SS, et al. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation 2004; 110(10): 1245-1250.
8. Laryea M, Watt KD, Molinari M, et al. Metabolic syndrome in liver transplant recipients: prevalence and association with major vascular events. Liver Transpl 2007; 13(8): 1109-1114.
9. Saab S, Shpaner A, Zhao Y, et al. Prevalence and risk factors for diabetes mellitus in moderate term survivors of liver transplantation. Am J Transplant 2006; 6(8): 1890-1895.
10. Stegall MD, Everson G, Schroter G, et al. Metabolic complications after liver transplantation. Diabetes, hypercholesterolemia, hypertension, and obesity. Transplantation 1995; 60(9): 1057-1060.
11. Gisbert C, Prieto M, Berenguer M, et al. Hyperlipidemia in liver transplant recipients: prevalence and risk factors. Liver Transpl Surg 1997; 3(4): 416-422.
12. Richards J, Gunson B, Johnson J, Neuberger J. Weight gain and obesity after liver transplantation. Transpl Int 2005; 18(4): 461-466.
13. Rego LO, Lima AS. Post-liver transplant obesity and diabetes. Curr Opin Clin Nutr Metab Care 2003; 6(4): 457-460.
14. Marchetti P, Navalesi R. The metabolic effects of cyclosporin and tacrolimus. J Endocrinol Invest 2000; 23(7): 482-490.
15. Hakeam HA, Al-Jedai AH, Raza SM, Hamawi K. Sirolimus induced dyslipidemia in tacrolimus based vs. tacrolimus free immunosuppressive regimens in renal transplant recipients. Ann Transplant 2008; 13(2): 46-53.
16. Laish I, Braun M, Mor E, et al. Metabolic syndrome in liver transplant recipients: prevalence, risk factors, and association with cardiovascular events. Liver Transpl 2011; 17(1): 15-22.
17. John PR, Thuluvath PJ. Outcome of patients with new-onset diabetes mellitus after liver transplantation compared with those without diabetes mellitus. Liver Transpl 2002; 8(8): 708-713.
18. Navasa M, Bustamante J, Marroni C, et al. Diabetes mellitus after liver transplantation: prevalence and predictive factors. J Hepatol 1996; 25(1): 64-71.
19. Trail KC, McCashland TM, Larsen JL, et al. Morbidity in patients with posttransplant diabetes mellitus following orthotopic liver transplantation. Liver Transpl Surg 1996; 2(4): 276-283.
20. Ericzon B, Groth C, Bismuth H, et al. Glucose metabolism in liver transplant recipients treated with FK 506 or cyclosporin in the European multicentre study. Transpl Int 1994; 7 Suppl 1: S11-S14.
21. Baid S, Cosimi AB, Farrell ML, Pascual M., et al. Posttransplant diabetes mellitus in liver transplant recipients: risk factors, temporal relationship with hepatitis C virus allograft hepatitis, and impact on mortality. Transplantation 2001; 72(6): 1066-1072.
22. Steinmuller TH, Stockmann M, Bechstein WO, et al. Liver transplantation and diabetes mellitus. Exp Clin Endocrinol Diabetes 2000; 108(6): 401-405.
23. Khalili M, Lim JW, Bass N, et al. New onset diabetes mellitus after liver transplantation: the critical role of hepatitis C infection. Liver Transpl 2004; 10(3): 349-355.
24. Jain AB, Kashyap R, Rakela J, Starzl TE, Fung JJ. Primary adult liver transplantation under tacrolimus: more than 90 months actual follow-up survival and adverse events. Liver Transpl Surg 1999; 5(2): 144-150.
25. Wahlstrom HE, Cooper J, Gores G, et al. Survival after liver transplantation in diabetics. Transplant Proc 1991; 23(1 Pt 2): 1565-1566.
26. Bigam DL, Pennington JJ, Carpentier A, et al. Hepatitis C-related cirrhosis: a predictor of diabetes after liver transplantation. Hepatology 2000; 32(1): 87-90.
27. AlDosary AA, Ramji AS, Elliott TG, et al. Post-liver transplantation diabetes mellitus: an association with hepatitis C. Liver Transpl 2002; 8(4): 356-361.
28. Oufroukhi L, Kamar N, Muscari F, et al. Predictive factors for posttransplant diabetes mellitus within one-year of liver transplantation. Transplantation 2008; 85(10): 1436-1442.
29. Caronia S, Taylor K, Pagliaro L, et al. Further evidence for an association between non-insulin-dependent diabetes mellitus and chronic hepatitis C virus infection. Hepatology 1999; 30(4): 1059-1063.
30. Mirabella S, Brunati A, Ricchiuti A, et al. New-onset diabetes after liver transplantation. Transplant Proc 2005; 37(6): 2636-2637.
31. Kuo HT, Sampaio MS, Ye X, et al. Risk factors for new-onset diabetes mellitus in adult liver transplant recipients, an analysis of the Organ Procurement and Transplant Network/United Network for Organ Sharing database. Transplantation 2010; 89(9): 1134-1140.
32. Saliba F, Lakehal M, Pageaux GP, et al. Risk factors for new-onset diabetes mellitus following liver transplantation and impact of hepatitis C infection: an observational multicenter study. Liver Transpl 2007; 13(1): 136-144.
33. Driscoll CJ, Cashion AK, Hathaway DK, et al. Posttransplant diabetes mellitus in liver transplant recipients. Prog Transplant 2006; 16(2): 110-116.
34. Parolin MB, Zaina FE, Araujo MV, Kupka E, Coelho JC. Prevalence of new-onset diabetes mellitus in Brazilian liver transplant recipients: association with HCV infection. Transplant Proc 2004; 36(9): 2776-2777.
35. Chen T, Jia H, Li J, et al. New onset diabetes mellitus after liver transplantation and hepatitis C virus infection: meta-analysis of clinical studies. Transpl Int 2009; 22(4): 408-415.
36. Shah T, Kasravi A, Huang E, et al. Risk factors for development of new-onset diabetes mellitus after kidney transplantation. Transplantation 2006; 82(12): 1673-1676.
37. Sumrani NB, Delaney V, Ding ZK, et al. Diabetes mellitus after renal transplantation in the cyclosporine era--an analysis of risk factors. Transplantation 1991; 51(2): 343-347.
38. Thuluvath PJ, John PR. Association between hepatitis C, diabetes mellitus, and race. a case-control study. Am J Gastroenterol 2003; 98(2): 438-441.
39. Saliba F, Lakehal M, Pageaux GP, et al. Risk factors for new-onset diabetes mellitus following liver transplantation and impact of hepatitis C infection: an observational multicenter study. Liver Transpl 2007; 13(1): 136-144.
40. Allison ME, Wreghitt T, Palmer CR, Alexander GJ. Evidence for a link between hepatitis C virus infection and diabetes mellitus in a cirrhotic population. J Hepatol 1994; 21(6): 1135-1139.
41. Knobler H, Stagnaro-Green A, Wallenstein S, Schwartz M, Roman SH. Higher incidence of diabetes in liver transplant recipients with hepatitis C. J Clin Gastroenterol 1998; 26(1): 30-33.
42. Kingston ME, Ali MA, Atiyeh M, Donnelly RJ. Diabetes mellitus in chronic active hepatitis and cirrhosis. Gastroenterology 1984; 87(3): 688-694.
43. Nolte W, Hartmann H, Ramadori G. Glucose metabolism and liver cirrhosis. Exp Clin Endocrinol Diabetes 1995; 103(2): 63-74.
44. Petrides AS, Vogt C, Schulze-Berge D, Matthews D, Strohmeyer G. Pathogenesis of glucose intolerance and diabetes mellitus in cirrhosis. Hepatology 1994; 19(3): 616-627.
45. Proietto J, Alford FP, Dudley FJ. The mechanism of the carbohydrate intolerance of cirrhosis. J Clin Endocrinol Metab 1980; 51(5): 1030-1036.
46. Aytug S, Reich D, Sapiro LE, Bernstein D, Begum N. Impaired IRS-1/PI3-kinase signaling in patients with HCV: a mechanism for increased prevalence of type 2 diabetes. Hepatology 2003; 38(6): 1384-1392.
47. Street A, Macdonald A, McCormick C, Harris M. Hepatitis C virus NS5A-mediated activation of phosphoinositide 3-kinase results in stabilization of cellular beta-catenin and stimulation of betacatenin- responsive transcription. J Virol 2005; 79(8): 5006-5016.
48. Harman-Boehm I, Zingman L, Hilzenrat N. No evidence for antiislet autoimmunity in diabetes mellitus associated with chronic hepatitis C infection. Hepatology 1999; 30(1): 342.
49. Hieronimus S, Fredenrich A, Tran A, Benzaken S, Fenichel P. Antibodies to GAD in chronic hepatitis C patients. Diabetes care 1997; 20(6): 1044.
50. Knobler H, Schihmanter R, Zifroni A, Fenakel G, Schattner A. Increased risk of type 2 diabetes in noncirrhotic patients with chronic hepatitis C virus infection. Mayo Clin Proc 2000; 75(4): 355-359.
51. Mason AL, Lau JY, Hoang N, et al. Association of diabetes mellitus and chronic hepatitis C virus infection. Hepatology 1999; 29(2): 328-333.
52. Laskus T, Radkowski M, Wang LF, Vargas H, Rakela J. Search for hepatitis C virus extrahepatic replication sites in patients with acquired immunodeficiency syndrome: specific detection of negative-strand viral RNA in various tissues. Hepatology 1998; 28(5): 1398-1401.
53. Magy N, Cribier B, Schmitt C, et al. Effects of corticosteroids on HCV infection. Int J Immunopharmacol 1999; 21(4): 253-261.
54. Heisel O, Heisel R, Balshaw R, Keown P. New onset diabetes mellitus in patients receiving calcineurin inhibitors: a systematic review and meta-analysis. Am J transplant 2004; 4(4): 583-595.
55. Perez MJ, Garcia DM, Taybi BJ, et al. Cardiovascular risk factors after liver transplantation: analysis of related factors. Transplant Proc 2011; 43(3): 739-741.
56. Plosker GL, Foster RH. Tacrolimus: a further update of its pharmacology and therapeutic use in the management of organ transplantation. Drugs 2000; 59(2): 323-389.
57. Hahn HJ, Laube F, Lucke S, et al. Toxic effects of cyclosporine on the endocrine pancreas of Wistar rats. Transplantation 1986; 41(1): 44-47.
58. Hirano Y, Fujihira S, Ohara K, et al. Morphological and functional changes of islets of Langerhans in FK506-treated rats. Transplantation 1992; 53(4): 889-894.
59. Nielsen JH, Mandrup-Poulsen T, Nerup J. Direct effects of cyclosporin A on human pancreatic beta-cells. Diabetes 1986; 35(9): 1049-1052.
60. Wahlstrom HE, Akimoto R, Endres D, Kolterman O, Moossa AR. Recovery and hypersecretion of insulin and reversal of insulin resistance after withdrawal of short-term cyclosporine treatment. Transplantation 1992; 53(6): 1190-1195.
61. Hahn HJ, Dunger A, Laube F, et al. Reversibility of the acute toxic effect of cyclosporin A on pancreatic B cells of Wistar rats. Diabetologia 1986; 29(8): 489-494.
62. Ekstrand AV, Eriksson JG, Gronhagen-Riska C, Ahonen PJ, Groop LC. Insulin resistance and insulin deficiency in the pathogenesis of posttransplantation diabetes in man. Transplantation 1992; 53(3): 563-569.
63. Krentz AJ, Dousset B, Mayer D, et al. Metabolic effects of cyclosporin A and FK 506 in liver transplant recipients. Diabetes 1993; 42(12): 1753-1759.
64. Vivarelli M, Dazzi A, Cucchetti A, et al. Sirolimus in liver transplant recipients: a large single-center experience. Transplant Proc 2010; 42(7): 2579-2584.
65. Bianchi G, Marchesini G, Marzocchi R, Pinna AD, Zoli M. Metabolic syndrome in liver transplantation: relation to etiology and immunosuppression. Liver Transpl 2008; 14(11): 1648-1654.
66. Chan JC, Cockram CS, Critchley JA. Drug-induced disorders of glucose metabolism. Mechanisms and management. Drug Saf 1996; 15(2): 135-157.
67. Markell M. New-onset diabetes mellitus in transplant patients: pathogenesis, complications, and management. Am J Kidney Dis 2004; 43(6): 953-965.
68. Crutchlow MF, Bloom RD. Transplant-associated hyperglycemia: a new look at an old problem. Clin J Am Soc Nephrol 2007; 2(2): 343-355.
69. Standards of medical care in diabetes-2011. Diabetes care 2011; 34 Suppl 1: S11-S61.
70. Davidson J, Wilkinson A, Dantal J, et al. New-onset diabetes after transplantation: 2003 International consensus guidelines. Proceedings of an international expert panel meeting. Barcelona, Spain, 19 February 2003. Transplantation 2003; 75(10 Suppl): SS3-SS24.
71. Lane JT, Dagogo-Jack S. Approach to the Patient with New-Onset Diabetes after Transplant (NODAT). J Clin Endocrinol Metab 2011; 96(11): 3289-3297.
72. Wilkinson A, Davidson J, Dotta F, et al. Guidelines for the treatment and management of new-onset diabetes after transplantation. Clinical transplantation 2005; 19(3): 291-298.
73. Marchetti P. New-onset diabetes after liver transplantation: from pathogenesis to management. Liver Transpl 2005; 11(6): 612-620.
74. Neumiller JJ. Clinical pharmacology of incretin therapies for type 2 diabetes mellitus: implications for treatment. Clin Ther 2011; 33(5): 528-576.
75. Migoya EM, Stevens CH, Bergman AJ, et al. Effect of moderate hepatic insufficiency on the pharmacokinetics of sitagliptin. Can J Clin Pharmacol 2009; 16(1): e165-170.
76. Davidson JA, Wilkinson A, International Expert Panel on New- Onset Diabetes after T. New-Onset Diabetes After Transplantation 2003 International Consensus Guidelines: an endocrinologist's view. Diabetes Care 2004; 27(3): 805-812.
77. Vincenti F, Schena FP, Paraskevas S, et al. A randomized, multicenter study of steroid avoidance, early steroid withdrawal or standard steroid therapy in kidney transplant recipients. Am J Transplant 2008; 8(2): 307-316.
78. Luan FL, Steffick DE, Gadegbeku C, et al. Graft and patient survival in kidney transplant recipients selected for de novo steroid-free maintenance immunosuppression. Am J Transplant 2009; 9(1): 160-168.
79. Redmon JB, Olson LK, Armstrong MB, et al. Effects of tacrolimus (FK506) on human insulin gene expression, insulin mRNA levels, and insulin secretion in HIT-T15 cells. J Clin Invest 1996; 98(12): 2786-2793.
80. Dumortier J, Bernard S, Bouffard Y, Boillot O. Conversion from tacrolimus to cyclosporine in liver transplanted patients with diabetes mellitus. Liver Transpl 2006; 12(4): 659-664.